Rectal cancer accounts for roughly one-third of all colorectal cancer diagnoses, making it one of the more common cancers in both men and women. In the United States alone, colorectal cancer produced over 160,000 new cases in 2022, with rectal cancer representing a significant share. While overall colorectal cancer rates have been declining in older adults thanks to screening, the disease is becoming notably more common in younger people, a trend that has reshaped screening guidelines and raised new questions about risk.
Incidence in the United States
Colorectal cancer is the third most commonly diagnosed cancer in the U.S. for both men and women. The country recorded roughly 160,186 new colorectal cases in 2022. Rectal cancer specifically makes up about 30 to 35 percent of that total, which translates to tens of thousands of new rectal cancer diagnoses each year. Men are diagnosed at slightly higher rates than women, though the gap has been narrowing over time.
The Rise in Younger Adults
One of the most striking trends in rectal cancer is how quickly it’s increasing among people under 50. Between 2008 and 2017, early-onset colorectal cancer (diagnosed in adults ages 20 to 49) rose by an average of 3.7% per year across the U.S., Australia, Canada, and England. That increase was even steeper in the youngest group: among adults ages 20 to 39, incidence climbed by 7.0% per year overall, with women seeing an 8.4% annual increase compared to 5.6% in men.
Rectal cancer appears to be a particular driver of this early-onset trend. Younger patients are more likely to be diagnosed with cancers in the rectum or distal colon compared to older adults. The reasons aren’t fully understood, but shifts in diet, obesity rates, and lifestyle factors that began in the 1970s and 1980s may be contributing to what researchers describe as a cohort effect, where people born in more recent decades carry higher risk than those born earlier.
This rapid rise is exactly why the U.S. Preventive Services Task Force lowered the recommended screening age from 50 to 45 in 2021. The CDC now advises that most people should begin screening for colorectal cancer soon after turning 45, with routine screening recommended through age 75.
Racial and Ethnic Disparities
Rectal cancer doesn’t affect all groups equally. Non-Hispanic Black individuals have some of the highest colorectal cancer incidence and mortality rates in the country. They’re also more likely to be diagnosed at an advanced stage: 25% of non-Hispanic Black patients are diagnosed with metastatic colorectal cancer, compared to 21% of non-Hispanic White patients. That difference in staging has a direct impact on survival outcomes.
Both non-Hispanic Black and Hispanic patients tend to be diagnosed at younger ages and with more advanced disease compared to non-Hispanic White patients. These disparities likely reflect a combination of factors including differences in screening access, insurance coverage, and the timeliness of follow-up care after symptoms appear.
Stage at Diagnosis
How early rectal cancer is caught makes an enormous difference. Based on U.S. data from 2018 to 2022, about 1 in 3 colorectal cancers were diagnosed at a localized stage, meaning the cancer hadn’t spread beyond the colon or rectum. Nearly 4 in 10 were found at a regional stage, where the cancer had reached nearby lymph nodes or tissues. About 2 in 10 were discovered at a distant stage, meaning the cancer had already spread to other parts of the body.
That distribution matters because survival rates vary dramatically by stage. For rectal cancer specifically, the five-year relative survival rate is 90% when the disease is caught at a localized stage. That drops to 74% for regional disease and 18% for distant disease. The combined five-year survival rate across all stages is 67%. These numbers, drawn from patients diagnosed between 2014 and 2020, reflect how pivotal early detection is.
How Rates Compare Globally
Colorectal cancer rates vary widely around the world, and the pattern closely tracks with economic development and Western dietary habits. The countries with the highest age-adjusted incidence rates in 2022 were Denmark (48.1 per 100,000), Norway (45.3), Hungary (44.2), the Netherlands (42.8), and Croatia (41.1). These Northern and Central European countries consistently rank at the top.
In terms of raw case numbers, China led the world with over 517,000 new colorectal cancer cases in 2022, followed by the U.S. (160,186) and Japan (145,756). But when adjusted for population size and age, Japan’s rate (36.6 per 100,000) was considerably higher than the U.S. rate (27.0). Countries like India, despite large populations, had much lower age-adjusted rates (4.9 per 100,000), reflecting different dietary patterns and lifestyle exposures.
Men face higher rates than women almost everywhere. In Hungary, the age-adjusted rate for men reached 62.4 per 100,000 in 2022, compared to Norway’s rate of 43.6 for women, the highest female rate recorded. The gender gap suggests that hormonal factors, dietary habits, or alcohol consumption patterns may play a role alongside shared environmental risks.
What Drives Rectal Cancer Risk
Several well-established factors increase the likelihood of developing rectal cancer. A diet high in processed and red meat, low physical activity, obesity, smoking, and heavy alcohol use all raise risk. Having a first-degree relative with colorectal cancer roughly doubles your own risk. Inflammatory bowel conditions, particularly ulcerative colitis and Crohn’s disease affecting the rectum, also increase susceptibility over time.
The global pattern reinforces this: countries with higher rates of processed food consumption, sedentary lifestyles, and obesity tend to have the highest colorectal cancer incidence. As countries in Asia and South America adopt more Western diets and activity levels, their rates have been climbing as well, suggesting these are modifiable risks rather than purely genetic ones.